Add to Favorites Newsroom RSS Share
Philadelphia, PA USA

Our News on Newswise

Wistar and Ben Franklin Technology Partners of Southeastern Pa. Forge Collaboration to Accelerate Technology Commercialization

Wistar and Ben Franklin Technology Partners of Southeastern Pennsylvania (Ben Franklin), a nonprofit conglomerate of partners providing direct/seed funding, mentorship and networks to strengthen enterprise development, have signed a Memorandum of...
27-Apr-2018 12:05 PM EDT Add to Favorites

Targeting Telomerase as a Therapeutic Strategy for Difficult-to-Treat Melanoma

Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in...
25-Apr-2018 12:05 PM EDT Add to Favorites

Wistar Team Receives Prestigious Award from National Clinical Research Forum for DNA-based Zika Research

Wistar and partners at the Perelman School of Medicine, University of Pennsylvania; Inovio Pharmaceuticals; and GeneOne Life Science were recognized among the Top 10 Clinical Research Achievement Awards by the Clinical Research Forum for their...
19-Apr-2018 10:05 AM EDT Add to Favorites

Top HIV Cure Research Team Refutes Major Recent Results on How to Identify HIV Persistence

An international team focused on HIV cure research spearheaded by The Wistar Institute in collaboration with the University of Pennsylvania and Vall d’Hebron Research Institute (VHIR) in Barcelona, Spain, established that the CD32 molecule is not...
18-Apr-2018 10:20 AM EDT Add to Favorites


Soluble Antibodies Play Immune Suppressive Role in Tumor Progression

Wistar researchers have found that soluble antibodies promote tumor progression by inducing accumulation of myeloid-derived suppressor cells (MDSCs) in pre-clinical cancer models.
12-Apr-2018 2:05 PM EDT Add to Favorites

Novel Combination Therapy Effective for NRAS Mutant and Therapy Resistant Melanoma

Wistar researchers have identified a novel therapeutic vulnerability in NRAS mutant melanoma and an effective strategy to address it, using a combination of two clinically relevant inhibitors, according to study results published online in EMBO...
11-Apr-2018 2:05 PM EDT Add to Favorites

Repurposing Existing FDA-Approved Inhibitors May Provide New Treatment Approach for Ovarian Cancer

Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
27-Mar-2018 12:00 PM EDT Add to Favorites


Wistar and YourEncore Unite to Advance Life Sciences Opportunities

Wistar and YourEncore, Inc., a life sciences and consumer goods consulting company engaging highly experienced, top talent industry experts, have signed a Memorandum of Understanding (MoU) to help accelerate the advancement of Wistar's early-stage...
23-Mar-2018 1:05 PM EDT Add to Favorites

see all news

Our YouTube Videos

Chat now!